Evolving Paradigms in NMOSD and MOGAD Immunotherapy

Recent breakthroughs in neuroimmunology have transformed the management of central nervous system inflammatory disorders. The introduction of high-precision cell-based assays has enabled clinicians to differentiate aquaporin-4 antibody neuromyelitis optica spectrum disorder (AQP4-Ab NMOSD) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Concurrently, targeted biologic agents have substantially reduced relapse rates and improved long-term functional recovery. Because many patients now maintain prolonged clinical remission, clinicians frequently face questions regarding the optimal duration of therapy. Consequently, tailoring NMOSD and MOGAD immunotherapy has emerged as a central priority in neuroimmunological practice.

However, de-escalating or stopping immunosuppression carries distinct clinical risks across these two disease entities. AQP4-Ab NMOSD is an aggressive astrocytopathy characterized by severe disability accumulation. In contrast, MOGAD often follows a more benign, sometimes monophasic trajectory. Therefore, practitioners cannot apply a uniform treatment cessation strategy across all antibody-mediated central nervous system disorders. Instead, physicians must carefully weigh disease severity, antibody persistence, and therapeutic adverse effects. Balancing these factors ensures that patients avoid both unnecessary drug toxicity and catastrophic disease reactivations. As clinical experience expands, structured protocols for treatment de-escalation are becoming vital tools in modern neuroimmunology.

Risk Profiles and Management in AQP4-Ab NMOSD

In AQP4-Ab NMOSD, therapeutic decisions demand exceptional caution. Clinical attacks in this condition are typically severe, unpredictable, and cause permanent neurological damage. Relapses often present as longitudinally extensive transverse myelitis or severe optic neuritis, leading to motor deficits or blindness. Observational registries consistently demonstrate that treatment cessation results in disease reactivation in over eighty percent of patients. Therefore, complete discontinuation of maintenance immunotherapy is not recommended in AQP4-Ab NMOSD under routine circumstances.

Nevertheless, clinicians may consider cautious de-escalation in highly selected individuals. Candidates for dose adjustment generally include patients who have achieved sustained clinical and radiologic stability for several years. Furthermore, de-escalation is often driven by treatment-related toxicity, severe recurrent infections, or significant medical comorbidities. In these situations, extending the dosing intervals of B-cell-depleting therapies or lowering immunosuppressive doses may minimize adverse effects. However, clinicians must remember that relapse risk persists even during gradual de-escalation. Consequently, every dose modification requires thorough patient counseling and rigorous neuroimaging surveillance to detect subclinical disease activity promptly.

Strategies for De-Escalation and Discontinuation in MOGAD

In contrast to NMOSD, MOGAD demonstrates remarkable clinical heterogeneity and a different immunological course. Pediatric patients frequently experience a monophasic illness with favorable functional recovery following initial acute therapy. Moreover, observational studies show that relapse rates in adults often decline substantially after several years of disease stability. Because persistent immunosuppression carries cumulative risks of infection and metabolic dysfunction, treatment de-escalation represents a practical option for many stable MOGAD patients.

Recent multicenter cohort investigations suggest that complete treatment discontinuation is feasible in selected MOGAD cases. Specifically, clinicians may consider discontinuing maintenance therapy after two to five years of continuous remission. Patients who experience antibody seroconversion from positive to negative represent the safest candidates for withdrawal. For patients on maintenance intravenous immunoglobulin or anti-CD20 therapy, clinicians can slowly extend treatment intervals before full cessation. However, physicians must maintain vigilance because some seronegative individuals may still experience delayed relapses. Therefore, clinicians must establish clear rescue treatment pathways and monitor patients closely following any immunotherapy reduction.

Navigating Challenges in Seronegative Disease and Special Populations

Seronegative NMOSD presents a unique clinical dilemma for neuroimmunologists. In this cohort, patients fulfill clinical diagnostic criteria for NMOSD but lack detectable AQP4 or MOG autoantibodies. Because therapeutic clinical trials generally exclude seronegative individuals, evidence-based treatment algorithms remain limited. Disease relapses can be disabling, yet no specific biologic therapies hold formal regulatory approvals for this subgroup. Consequently, treatment choices rely heavily on expert consensus and empiric immunosuppressive protocols.

Some specialists suggest that clinicians may cautiously explore treatment discontinuation after five years of documented clinical stability in seronegative patients. However, this recommendation stems solely from expert opinion rather than prospective trials. In addition, special clinical scenarios, such as pregnancy, require nuanced therapeutic adjustments. During pregnancy, physicians must balance the maternal risk of relapse against potential fetal teratogenicity. Clinicians often continue low-risk monoclonal antibodies or corticosteroids while deferring or tapering higher-risk immunosuppressants. Thus, shared decision-making between neurologists and obstetricians is crucial to ensure maternal stability and fetal safety throughout gestation.

Clinical Monitoring and Biomarker-Guided Decision Making

Safe treatment modification requires dependable monitoring tools to identify impending disease reactivations before clinical relapse occurs. Serial contrast-enhanced magnetic resonance imaging (MRI) of the brain and spinal cord serves as the cornerstone for detecting asymptomatic inflammatory lesions. In addition, optical coherence tomography (OCT) provides precise measurements of retinal nerve fiber layer thickness, enabling clinicians to identify subclinical optic pathway axonal loss. Integrating these imaging modalities allows physicians to assess structural integrity during treatment de-escalation.

Furthermore, emerging fluid biomarkers are gaining substantial attention in neuroimmunology. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) show promise as sensitive markers of active neuroaxonal injury and astrocytic damage. Longitudinal autoantibody titer tracking also aids in risk stratification, particularly in MOGAD where antibody clearance correlates with lower relapse hazards. However, fluid biomarkers currently lack universal standardization for routine clinical practice. Therefore, clinicians must integrate biomarker trends with detailed physical examinations and advanced neuroimaging. This multimodal surveillance framework empowers healthcare providers to intervene rapidly if subclinical disease activity re-emerges.

Future Directions and Individualized Care Protocols

The management of central nervous system antibody-mediated disorders is rapidly advancing toward personalized neuroimmunology. As therapeutic agents continue to expand, clinicians must move beyond empirical maintenance schedules toward evidence-based discontinuation protocols. Currently, most available data derive from retrospective cohorts and observational registries, which contain inherent selection biases. Consequently, prospective randomized trials are urgently needed to establish validated guidelines for de-escalation in both adult and pediatric populations.

Moreover, future research must evaluate the health-economic implications of long-term biologic therapies. Reducing therapy frequency not only decreases the incidence of opportunistic infections and hypogammaglobulinemia but also eases healthcare expenditure. International patient registries will play a pivotal role in tracking real-world outcomes following drug tapering. Ultimately, successful management requires clinicians to maintain an open dialogue with patients, weighing personal treatment preferences against clinical relapse vulnerabilities. By combining standardized clinical monitoring, biomarker surveillance, and individualized risk assessment, neurologists can achieve durable disease control while minimizing unnecessary therapeutic burdens.

Frequently Asked Questions

Can patients with AQP4-positive NMOSD safely discontinue immunotherapy?

Clinicians should avoid stopping maintenance therapy in AQP4-positive NMOSD because relapses cause severe permanent neurological disability. Over eighty percent of patients experience disease reactivation following cessation. While selected individuals in long-term remission may undergo cautious dose de-escalation, complete discontinuation remains unsafe and is strongly discouraged in routine clinical neuroimmunology practice.

When can clinicians consider discontinuing treatment in MOGAD?

Treatment discontinuation in MOGAD is feasible after two to five years of sustained clinical remission. This strategy applies particularly to pediatric cohorts or patients who achieve persistent serum antibody seronegativity. However, clinicians must conduct regular follow-up because clinical relapses may still occur, requiring prompt reinstitution of effective rescue or maintenance immunotherapy.

How should therapy be managed during pregnancy in NMOSD and MOGAD?

Pregnancy management requires balancing maternal disease suppression against potential fetal drug toxicity. Clinicians often continue selected therapies with established safety profiles, such as monoclonal antibodies or corticosteroids, while tapering higher-risk agents. Close multidisciplinary coordination ensures optimal maternal stability and minimizes gestational complications without exposing the fetus to avoidable pharmacological hazards.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Treatment decisions should always be made by a qualified healthcare professional based on individual patient assessment. Refer to the latest local and national guidelines for clinical practice.

References

1. Hacohen Y et al. De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD. Neurology. 2026 Sep 22. doi: 10.1212/WNL.0000000000218482. PMID: 42647788.


2. Boudot de la Motte M, Cobo-Calvo A, Marignier R. Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. JAMA Neurol. 2026;83(5):512-520.


3. Kim SH, Mealy MA, Levy M, et al. Outcomes of Immunosuppressive Therapy Discontinuation in Patients With Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder. Mult Scler. 2023;29(8):985-994.